On Friday, Trump revived the once-scrapped plan to eliminate rebates that drugmakers pay to pharmacy benefit managers with an executive order this summer. But the order also stated that the rebate plan could not raise patients’ costs or taxpayer spending. Regulators projected that the original rule would raise federal spending by nearly $200 billion over 10 years — so the new rule could look pretty different. Read more here.
(Source: Sarah Ohwermole; Politico; 11/19/20)